» Download Public Reports
About 700 reports
- Company report
- January 2013
- 4 pages
- by Corporation
... Associated with juxtapid treatment may be a risk factor for progressive liver disease, including steatohepatitis and cirrhosis. Measure alt, ast, alkaline phosphatase, and total bilirubin before initiating ...
December 2012
... Approved age groups as soon as possible. In the u.S. The pediatric label extension is currently under review by the fda. In september 2012, intercell S partner biological e. Ltd. Launched the je vaccine ...
December 2012
... The strongest contributor to performance for december. The great run of the liver cancer treatment company continued to the end of 2012 with the company being officially included, due to its rise in market ...
December 2012
... And europe that evaluated halaven as a potential second-line chemotherapy for the treatment of breast cancer, the group is currently preparing for submission of applications seeking approval for additional ...
January 2013
... It comes to cancer management, the phenomenon of quality of life is regarded as a multi-dimensional concept and it involves patients social, emotional and physical well being.7 It would be worth mentioning ...
February 2013
... Million respectively) as part of our policy of flexible capital policy and as a means of returning profits to our shareholders. An announcement was made on november 29, 2012 that sucampo pharmaceutical ...
April 2013
... Of activities aimed at promoting disease education and awareness as a part of comprehensive efforts to eliminate lymphatic filariasis. In addition, the group has formed partnerships with a wide range ...
March 2013
... Costs were to increase as multiple clinical trials are conducted simultaneously). 3Dm was planning on starting clinical trials for several pipeline applications, such as its alveolar bone reconstruction ...
April 2013
... And insurance for clinical research besides trials a lot of clinical research not covered by the pharmaceutical affairs act is conducted in many education-related hospitals such as university hospitals ...
» Purchase Premium Reports
(From $ 125 - $ 6 995)
About 1 500 reports
- $ 6 995
- Industry report
- February 2013
- by Global Data
Viviant/Combriza (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Viviant/Combriza (Osteoporosis) - Forecast and Market ...
February 2013
$ 6 995
Protelos (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Protelos (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Evista (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Evista (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Forteo (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Forteo (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Odanacatib (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
Reclast (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Reclast (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
